Nexentis Technologies (NXTS) News
NASDAQ: NXTSIndustrialsAgricultural ChemicalsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NXTS news summary
We found 5 recent headlines mentioning Nexentis Technologies (NXTS): 1 in the past week and 4 in the past 30 days, most often from GlobeNewswire. NXTS is making an outsized move today, down 7.06% at $1.58, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Nexentis: MitoCareX Progresses Toward In-Vitro Evaluation Following AI-Powered Computational Screening", was published by GlobeNewswire on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Nexentis Technologies headlines
- Nexentis: MitoCareX Progresses Toward In-Vitro Evaluation Following AI-Powered Computational ScreeningFurther computational prioritization by MitoCareX leads to selection and ordering of molecules for planned experimental assessmentGlobeNewswire
- Nexentis Announces Reverse Stock SplitNess Ziona, Israel, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based…GlobeNewswire
- Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with BoltzMitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigationGlobeNewswire
- Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening StageMitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigationGlobeNewswire
- Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway AnalysisMitoCareX expands its internal bioinformatics expertise to broaden the analysis of disease biology within its computational drug-discovery activitiesGlobeNewswire